MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Caladrius Biosciences Retained Earnings 2011-2025 | CLBS
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Caladrius Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -548 M | -528 M | -507 M | -453 M | -426 M | -417 M | -398 M | -382 M | -405 M | -372 M | -291 M | -236 M | -197 M | -143 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -143 M | -548 M | -379 M |
Quarterly Retained Earnings Caladrius Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -562 M | -557 M | -553 M | -548 M | -543 M | -539 M | -533 M | -528 M | -523 M | -517 M | -513 M | -507 M | -501 M | - | -457 M | -453 M | -446 M | -439 M | -434 M | -426 M | -426 M | -426 M | -426 M | -417 M | -417 M | -417 M | -417 M | -398 M | -398 M | -398 M | -398 M | -382 M | -382 M | -382 M | -382 M | -405 M | -405 M | -405 M | -405 M | -372 M | -372 M | -372 M | -372 M | -291 M | -291 M | -291 M | -291 M | -236 M | -236 M | -236 M | -236 M | -197 M | -197 M | -197 M | -197 M | -143 M | -143 M | -143 M | -143 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -143 M | -562 M | -383 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
-7.9 B | $ 223.01 | -0.99 % | $ 395 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
19.3 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
-191 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
-182 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
-1.07 B | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-371 M | - | - | $ 169 M | USA |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Cellectar Biosciences
CLRB
|
-203 M | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Clovis Oncology
CLVS
|
-2.88 B | - | -7.23 % | $ 13 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 0.29 | -5.01 % | $ 631 M | Israel |
 |
Cortexyme
CRTX
|
-320 M | - | -1.05 % | $ 67.1 M | USA |
 |
Benitec Biopharma
BNTC
|
-228 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-2.7 B | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Deciphera Pharmaceuticals
DCPH
|
-1.43 B | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-2.59 B | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | $ 10.89 | -0.09 % | $ 1.42 B | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-274 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |